LUMINOSITY

NCT03539536 📎

Regimen

Experimental
Telisotuzumab vedotin

Population

c-Met overexpressing EGFR-wildtype non-squamous NSCLC, ≤2 prior lines of therapy

Key finding

Teliso-V in c-MET high EGFR-WT non-squamous NSCLC: ORR 35% — basis for Emrelis accelerated approval.

Source: PMID 38843488

Timeline

  • Enrollment start: 2018-10-10 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.113)